Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible if the following criteria are met:~1. Ability to provide written informed consent and comply with study assessments for the full duration of the study.~2. Age \> 18 years~3. Non-infectious uveitis in study eye.~4. Stable anti-uveitis medical regimen for at least one month prior to injection and controlled uveitis in the judgment of the investigator.~5. Vision 20/40 or worse in study eye.~6. Cystoid Macular Edema (CME) on fluorescein angiography (FA)~7. Optical Coherence Tomography (OCT) demonstrating thickness greater than 300 microns in the central subfield.~8. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography.~Only one eye will be assessed in the study. If both eyes are eligible, the investigator will determine which eye will be entered into the study.~Exclusion Criteria:~1. Previous intravitreal triamcinolone injection in study eye within 3 months of study injection.~2. Use of more than two glaucoma medicines for study eye.~3. Significant epiretinal membrane as judged by treating physician.~4. Evidence of vitreomacular traction on OCT.~5. Previous vitrectomy in study eye.~6. Pregnancy (positive pregnancy test) or lactation.~7. Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an intrauterine device (IUD), or contraceptive hormone implant or patch.~8. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.~9. Participation in another simultaneous IND trial.~10. Treatment for CME with intravitreal Lucentis, Macugen, or Avastin within 6 weeks prior to enrollment in this study.~11. Uncontrolled inflammation in the study eye.~12. Current vitreous hemorrhage.~13. Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.~14. Known allergy to any component of the study drug.~15. Intraocular pressure \> 25 mm Hg despite treatment with glaucoma medications.~16. Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, the subject can become eligible.~17. Major non-ocular surgery planned during the next 6 months.~18. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.~19. No Avastin use permitted in fellow eye during study.~20. Unwilling or unable to follow or comply with all study related procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete